BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24552990)

  • 1. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
    Reynolds C; Roderick JE; LaBelle JL; Bird G; Mathieu R; Bodaar K; Colon D; Pyati U; Stevenson KE; Qi J; Harris M; Silverman LB; Sallan SE; Bradner JE; Neuberg DS; Look AT; Walensky LD; Kelliher MA; Gutierrez A
    Leukemia; 2014 Sep; 28(9):1819-27. PubMed ID: 24552990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.
    Greenhough A; Wallam CA; Hicks DJ; Moorghen M; Williams AC; Paraskeva C
    Oncogene; 2010 Jun; 29(23):3398-410. PubMed ID: 20348947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
    Rahmani M; Anderson A; Habibi JR; Crabtree TR; Mayo M; Harada H; Ferreira-Gonzalez A; Dent P; Grant S
    Blood; 2009 Nov; 114(20):4507-16. PubMed ID: 19773546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia.
    Gutierrez A; Grebliunaite R; Feng H; Kozakewich E; Zhu S; Guo F; Payne E; Mansour M; Dahlberg SE; Neuberg DS; den Hertog J; Prochownik EV; Testa JR; Harris M; Kanki JP; Look AT
    J Exp Med; 2011 Aug; 208(8):1595-603. PubMed ID: 21727187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
    Matsumoto T; Nagase Y; Iwasawa M; Yasui T; Masuda H; Kadono Y; Nakamura K; Tanaka S
    Arthritis Rheum; 2011 Dec; 63(12):3908-17. PubMed ID: 21898348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
    Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
    Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.
    Guijarro MV; Link W; Rosado A; Leal JF; Carnero A
    Carcinogenesis; 2007 Dec; 28(12):2443-50. PubMed ID: 17675338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bim is a suppressor of Myc-induced mouse B cell leukemia.
    Egle A; Harris AW; Bouillet P; Cory S
    Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6164-9. PubMed ID: 15079075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
    Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
    Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
    Coloff JL; Macintyre AN; Nichols AG; Liu T; Gallo CA; Plas DR; Rathmell JC
    Cancer Res; 2011 Aug; 71(15):5204-13. PubMed ID: 21670080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo.
    Sabbagh L; Pulle G; Liu Y; Tsitsikov EN; Watts TH
    J Immunol; 2008 Jun; 180(12):8093-101. PubMed ID: 18523273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.